A Phase 1/2 study of the highly-selective RET inhibitor, BLU-667, in patients with thyroid cancer, non-small cell lung cancer (NSCLC) and other advanced solid tumors. NCT03037385

Drilon A et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 2020;383(9):813-24. Abstract

Drilon AE et al. Registrational results of LIBRETTO-001: A Phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. IASLC 2019;Abstract PL02.08.

Drilon AE et al. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. ASCO 2018;Abstract 102.

Drilon AE et al. Targeting RET-driven cancers: Lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 2018;15(3):150. Abstract

Hong DS et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020;383(13):1207-17. Abstract

Recondo G et al. Targeting MET dysregulation in cancer. Cancer Discov 2020;10(7):922-34. Abstract

Schrok AB et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol 2016;11(9):1493-502. Abstract

Smit EF et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. ASCO 2020;Abstract 9503.

Wolfe J et al. Capmatinib in MET exon 14–mutated or MET-amplified non–small-cell lung cancer. N Engl J Med 2020;383(10):944-57. Abstract